Navigation Links
VioQuest Pharmaceuticals Announces Data Presentation for Its Akt,Inhibitor VQD-002, at American Association for Cancer Research,Annual Meeting

rrent expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurances that the FDA will approve VioQuest's planned NDA submission relating to Lenocta(TM) for the treatment of leishmaniasis, and even if approved, there is no assurance that VioQuest will be able to successfully commercialize Lenocta(TM) for the treatment of leishmaniasis or any other indication, or that VioQuest will receive any proceeds in connection with a sale or other disposition of its Chiral Quest division. Other risks and uncertainties include the possibility that the results of clinical trials will not support VioQuest's claims, the possibility that VioQuest's development efforts relating to its product candidates, including Lenocta(TM) and VQD-002, will not be successful, the inability to obtain regulatory approval of VioQuest's product candidates, VioQuest's reliance on third-party researchers to develop its product candidates, its lack of experience in developing and commercializing pharmaceutical products, and the possibility that its licenses to develop and commercialize its product candidates may be terminated. Additional risks are described in VioQuest's Annual Report on Form 10-KSB for the year ended December 31, 2006. VioQuest assumes no obligation and does not intend to update these forward-looking statements, except as required by law.

    Contact information:

    Daniel Greenleaf                     Brian Lenz

    President and CEO                    Chief Financial Officer

    908-766-4400 ext. 115                908-766-4400 ext. 117

          

dan.greenleaf@vioquestpharm.com brian.lenz@vioquestpharm.com

CONTACT: Daniel Greenleaf, President and CEO, +1-908-766-4400
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
(Date:8/20/2014)... MIRAGE, Calif. , Aug. 20, 2014 The ... named Fernando Davila has been successfully treated for ... disease", by Dr, Anibal R. Gauto , Medical Director ... Center, at Eisenhower Medical Center in Rancho Mirage, ... new treatment pioneered by Dr. John Crew at ...
(Date:8/20/2014)... 20, 2014 Research and Markets ... "Global Advanced Wound Care and Closure Market (Types, ... Global Trends, Company Profiles, Demand, Insights, Analysis, Research, ... report to their offering. ... and closure market (types, applications, end user and ...
(Date:8/20/2014)... PHOENIX , Aug. 20, 2014 /PRNewswire-USNewswire/ ... next-generation sequencing and proteomic diagnostics and biomarker driven ... collaboration with TESARO, Inc.  Paradigm will use its ... from clinical trials to better predict which patients ... may lead to more successful clinical trial outcomes ...
Breaking Medicine Technology:Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 2Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 3Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 4Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 5Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 6Global Advanced Wound Care and Closure Market (Types, Applications, End User and Geography) - Forecast to 2020 2Paradigm Announces Molecular Profiling Collaboration with TESARO, Inc. 2
(Date:8/20/2014)... Loss of brain cells that act as a "sleep ... falling and staying asleep, a new study suggests. ... and often results in nighttime confusion and wandering, according ... the Rush Memory and Aging Project, which includes nearly ... being followed until death, at which point their brains ...
(Date:8/20/2014)... HealthDay Reporter WEDNESDAY, Aug. 20, 2014 ... been an option, but a new study shows that only ... common reasons women didn,t undergo reconstruction was that they felt ... they were focused on their cancer treatment," said lead researcher ... Kettering Cancer Center, in New York City. Also common ...
(Date:8/20/2014)... one of the most persistent and deadliest infectious diseases ... each year. , Scientists who study tuberculosis have long ... spread from humans in Africa to seals and sea ... transmitted it to Native people there before Europeans landed ... Reveal Seals as a Source of New World Human ...
(Date:8/20/2014)... Salt Lake City, Utah (PRWEB) August 20, 2014 ... the Inc. 500’s 2014 list of the nation’s fastest growing ... overall growth in the health care sector. Connexion Point is ... specializes in contact centers in Medicare and Medicaid, and its ... in the nation. Connexion Point employs 1,000 people and has ...
(Date:8/20/2014)... YORK, NY (August 20, 2014) Research from Columbia ... critical role in stomach cancer growth and that blocking ... an effective treatment for the disease. The study was ... in collaboration with Duan Chen, MD, PhD, in Norway ... Translational Medicine . , "Scientists have long observed that ...
Breaking Medicine News(10 mins):Health News:Seniors' Sleep Woes May Be Linked to Loss of Brain Cells 2Health News:Many Women Who Have Mastectomy Don't Get Breast Reconstruction: Study 2Health News:Many Women Who Have Mastectomy Don't Get Breast Reconstruction: Study 3Health News:New research shows seals and sea lions likely spread tuberculosis to humans 2Health News:New research shows seals and sea lions likely spread tuberculosis to humans 3Health News:With 3943.8% Growth, Connexion Point, a Leader in Contact Centers for Health Care, Ranks 86th on the Inc. 500 List as One of the Nation’s Fastest Growing Companies 2Health News:Severing nerves may shrink stomach cancers: Botox injections slow growth of tumors in mice 2
... (Nasdaq: CYNO ), a leading developer and ... systems, today announced financial results for the three and ... Results Consistent with Cynosure,s January 15, 2009 announcement, ... were $25.5 million, reflecting the effect of deteriorating global ...
... Feb. 10 Novasys Medical, Inc., a developer of ... one of the nation,s leading health insurers with over ... treatment for stress urinary incontinence (SUI) in non-pregnant women ... undergo surgery for their condition. According to Aetna,s updated ...
... Kit Offers Extensive Enrollment Information and Insights into ... Feb. 10 HealthLeaders-InterStudy , a leading ... District Survival Kit designed to provide pharmaceutical sales ... and analysis that drives innovative sales strategy development.Each ...
... quarter decline in procedure volume rate shows signs of ... 48% Provides near-term financial outlook CINCINNATI, Feb. 10 ... LCAV ), a leading provider of laser vision correction ... financial and operating results for the three and 12 ...
... OSF HealthCare and Seattle Children,s Hospital among the ... software suiteCLEVELAND, Feb. 10 Healthcare organizations ... healthy lifestyle. Now, hospitals and health systems are ... preaching. Paper medical records cause costly errors, potentially ...
... AHPI ) reported that its net income for ... or zero cents per share in the,prior year period, to ... per,share, primarily because of lower sales volume in the current ... the second quarter fell about 8 percent, or almost $1.1,million, ...
Cached Medicine News:Health News:Cynosure Reports Financial Results for the Fourth Quarter and Full Year 2008 2Health News:Cynosure Reports Financial Results for the Fourth Quarter and Full Year 2008 3Health News:Cynosure Reports Financial Results for the Fourth Quarter and Full Year 2008 4Health News:Cynosure Reports Financial Results for the Fourth Quarter and Full Year 2008 5Health News:Cynosure Reports Financial Results for the Fourth Quarter and Full Year 2008 6Health News:Cynosure Reports Financial Results for the Fourth Quarter and Full Year 2008 7Health News:Cynosure Reports Financial Results for the Fourth Quarter and Full Year 2008 8Health News:Cynosure Reports Financial Results for the Fourth Quarter and Full Year 2008 9Health News:Cynosure Reports Financial Results for the Fourth Quarter and Full Year 2008 10Health News:Cynosure Reports Financial Results for the Fourth Quarter and Full Year 2008 11Health News:Cynosure Reports Financial Results for the Fourth Quarter and Full Year 2008 12Health News:Cynosure Reports Financial Results for the Fourth Quarter and Full Year 2008 13Health News:Aetna Now Covers Novasys Medical's Renessa(R) Treatment for Incontinence in Women 2Health News:HealthLeaders-InterStudy Offers District Survival Kit to Arm Pharmaceutical Sales Teams With Local-Level Managed Care Market Intelligence 2Health News:LCA-Vision Announces Fourth Quarter and Full Year 2008 Financial Results 2Health News:LCA-Vision Announces Fourth Quarter and Full Year 2008 Financial Results 3Health News:LCA-Vision Announces Fourth Quarter and Full Year 2008 Financial Results 4Health News:LCA-Vision Announces Fourth Quarter and Full Year 2008 Financial Results 5Health News:LCA-Vision Announces Fourth Quarter and Full Year 2008 Financial Results 6Health News:LCA-Vision Announces Fourth Quarter and Full Year 2008 Financial Results 7Health News:LCA-Vision Announces Fourth Quarter and Full Year 2008 Financial Results 8Health News:LCA-Vision Announces Fourth Quarter and Full Year 2008 Financial Results 9Health News:LCA-Vision Announces Fourth Quarter and Full Year 2008 Financial Results 10Health News:LCA-Vision Announces Fourth Quarter and Full Year 2008 Financial Results 11Health News:LCA-Vision Announces Fourth Quarter and Full Year 2008 Financial Results 12Health News:LCA-Vision Announces Fourth Quarter and Full Year 2008 Financial Results 13Health News:LCA-Vision Announces Fourth Quarter and Full Year 2008 Financial Results 14Health News:LCA-Vision Announces Fourth Quarter and Full Year 2008 Financial Results 15Health News:LCA-Vision Announces Fourth Quarter and Full Year 2008 Financial Results 16Health News:OnBase is the Choice for a Growing Number of Healthcare Organizations 2Health News:OnBase is the Choice for a Growing Number of Healthcare Organizations 3Health News:Allied Healthcare Reports Second Quarter Loss 2Health News:Allied Healthcare Reports Second Quarter Loss 3Health News:Allied Healthcare Reports Second Quarter Loss 4Health News:Allied Healthcare Reports Second Quarter Loss 5
... Our breadth of infectious disease ELISA ... field. With standard assay protocols for faster ... Disease ELISA products provide increased reliability and ... includes antibody detection assays for a wide ...
... of infectious disease ELISA products make us ... assay protocols for faster integration into the ... provide increased reliability and run-to-run consistency. Our ... assays for a wide range of serological ...
... Our breadth of infectious disease ELISA ... field. With standard assay protocols for faster ... Disease ELISA products provide increased reliability and ... includes antibody detection assays for a wide ...
... of infectious disease ELISA products make us ... assay protocols for faster integration into the ... provide increased reliability and run-to-run consistency. Our ... assays for a wide range of serological ...
Medicine Products: